SCHEMBL2095535

SCHEMBL2095535

COc1ccc(Cn2cc(C(=O)O)c(=O)c3c(C)c(C)c(N4C[C@@H]5C[C@H]4CN5)nc32)c(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.38
CHRNB2 P17787 2/20 0.37
CHRNA4 P43681 2/20 0.37
ALDH1A1 P00352 3/20 0.36
TSHR P16473 3/20 0.36
BTK Q06187 1/20 0.36
PDCD1 Q15116 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
GNRHR P30968 1/20 0.36
NTRK1 P04629 2/20 0.35
MAP4K1 Q92918 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TP53 P04637 1/20 0.35
MAP4K2 Q12851 1/20 0.35
STK4 Q13043 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2093636 0.90 HRH4 (0.38) HRH4CHRNB2CHRNA4ALDH1A1TSHR
SCHEMBL2094019 0.88 MAP4K1 (0.36) HRH4CHRNB2CHRNA4ALDH1A1TSHR
SCHEMBL2095977 0.87 DPP4 (0.43) HRH4CHRNB2CHRNA4ALDH1A1TSHR
SCHEMBL2092907 0.84 CHRM1 (0.37) HRH4ALDH1A1TSHRNTRK1MAP4K1
SCHEMBL2091973 0.81 GNRHR (0.40) HRH4GNRHRNTRK1MAP4K1TP53
SCHEMBL2094103 0.78 DPP4 (0.48) ALDH1A1NTRK1MAP4K1KMT2AKDM4E
SCHEMBL2092554 0.76 KMT2A (0.40) ALDH1A1TSHRMEN1KMT2AKDM4E
SCHEMBL4399915 0.76 TSHR (0.40) ALDH1A1TSHRBTKMEN1KMT2A
SCHEMBL2092621 0.75 CHRM1 (0.48)
SCHEMBL2095372 0.75 DPP4 (0.46) ALDH1A1NTRK1MAP4K1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030232818-A1 Antibacterial compounds ABBVIE INC. 2003-12-18 US claimed
US-8163769-B2 1,8-naphthyridine derivatives ABBOTT LABORATORIES (US) 2012-04-24 US disclosed
US-20030232818-A1 Antibacterial compounds ABBVIE INC. 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232818-A1 Antibacterial compounds PGLS, UGT1A1, CASP1 HRH4 3362/4885CHRNB2 4881/4885CHRNA4 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.